TABLE 4.
Health outcomes among patients matched to Pediatric Health Information System and Medicaid data
| Outcome (%) | DRZ-randomized trialsa |
P-value | All DRZ- assigned N=159b | P-valuec | |
|---|---|---|---|---|---|
| No DRZ-assigned N=74 | DRZ-assigned N=90 | ||||
|
| |||||
| Hard cardiovascular endpoints | 13 (17.6) | 5 (5.6) | 0.02 | 7 (4.4) | 0.002 |
| Cardiomyopathy | 6 (8.1) | 4 (4.4) | 0.35 | 6 (3.8) | 0.20 |
| Ischemic heart disease | 3 (4.1) | 0 | 0.09 | 0 | 0.03 |
| Stroke | 7 (9.5) | 1 (1.1) | 0.02 | 1 (0.6) | 0.002 |
| Other endpoints | |||||
| Valve disease | 4 (5.4) | 2 (2.2) | 0.41 | 6 (3.8) | 0.73 |
| Other vascular disease | 1 (1.4) | 3 (3.3) | 0.63 | 3 (1.9) | 1.00 |
| Arrhythmia | 13 (17.6) | 5 (5.6) | 0.02 | 10 (6.3) | 0.01 |
| Related cardiovascular risk factors | 20 (27.0) | 13 (14.4) | 0.05 | 20 (12.6) | 0.01 |
| Hypertension | 12 (16.2) | 10 (11.1) | 0.37 | 15 (9.4) | 0.19 |
| Dyslipidemia | 2 (2.7) | 0 | 0.20 | 1 (0.6) | 0.24 |
| Diabetes | 6 (8.1) | 2 (2.2) | 0.14 | 4 (2.5) | 0.08 |
| Kidney disease | 7 (9.5) | 4 (4.4) | 0.23 | 5 (3.1) | 0.06 |
| Acute myeloid leukemia/myelodysplasia | 4 (5.4) | 7 (7.8) | 0.76 | 8 (5.0) | >0.99 |
DRZ, dexrazoxane
a
P9404, P9425, P9426, and DFCI 95–01
b
Same as above but also P9754 where all patients were DRZ-assigned
c
Comparison between no DRZ-assigned (n=74) versus all DRZ-assigned, including P9754 (n=159); all p-values based on Fisher’s exact test